Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 35.23 Million USD | 86.75% |
| 2022 | 18.86 Million USD | 199.03% |
| 2021 | 6.3 Million USD | -11.15% |
| 2020 | 7.1 Million USD | -9.01% |
| 2019 | 7.8 Million USD | 61.54% |
| 2018 | 4.83 Million USD | -69.34% |
| 2017 | 15.75 Million USD | 18.57% |
| 2016 | 13.28 Million USD | -26.96% |
| 2015 | 18.19 Million USD | 909.67% |
| 2014 | 1.8 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 2.78 Million USD | 1010.32% |
| 2011 | 250.65 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 31.52 Million USD | 0.67% |
| 2024 Q1 | 31.31 Million USD | 0.0% |
| 2023 FY | 30.8 Million USD | 63.3% |
| 2023 Q3 | 34.33 Million USD | 79.54% |
| 2023 Q1 | 18.67 Million USD | -1.04% |
| 2023 Q2 | 19.12 Million USD | 2.42% |
| 2023 Q4 | 30.8 Million USD | -10.26% |
| 2022 Q3 | 19.03 Million USD | -1.65% |
| 2022 Q1 | 6.09 Million USD | -3.38% |
| 2022 Q4 | 18.86 Million USD | -0.87% |
| 2022 FY | 18.86 Million USD | 199.03% |
| 2022 Q2 | 19.35 Million USD | 217.44% |
| 2021 FY | 6.3 Million USD | -11.15% |
| 2021 Q4 | 6.3 Million USD | -3.18% |
| 2021 Q1 | 6.91 Million USD | -2.68% |
| 2021 Q3 | 6.51 Million USD | -3.01% |
| 2021 Q2 | 6.71 Million USD | -2.79% |
| 2020 Q3 | 7.28 Million USD | -2.4% |
| 2020 Q1 | 7.63 Million USD | -2.15% |
| 2020 Q2 | 7.46 Million USD | -2.24% |
| 2020 Q4 | 7.1 Million USD | -2.54% |
| 2020 FY | 7.1 Million USD | -9.01% |
| 2019 Q1 | 8.28 Million USD | 71.41% |
| 2019 FY | 7.8 Million USD | 61.54% |
| 2019 Q2 | 8.12 Million USD | -1.86% |
| 2019 Q3 | 7.96 Million USD | -1.96% |
| 2019 Q4 | 7.8 Million USD | -2.06% |
| 2018 Q3 | 7.87 Million USD | -27.73% |
| 2018 FY | 4.83 Million USD | -69.34% |
| 2018 Q4 | 4.83 Million USD | -38.66% |
| 2018 Q2 | 10.89 Million USD | -13.67% |
| 2018 Q1 | 12.62 Million USD | -19.88% |
| 2017 Q2 | 20.91 Million USD | -12.93% |
| 2017 Q1 | 24.01 Million USD | 80.73% |
| 2017 FY | 15.75 Million USD | 18.57% |
| 2017 Q4 | 15.75 Million USD | -11.57% |
| 2017 Q3 | 17.81 Million USD | -14.79% |
| 2016 Q2 | 18.26 Million USD | 0.16% |
| 2016 Q1 | 18.23 Million USD | 0.22% |
| 2016 FY | 13.28 Million USD | -26.96% |
| 2016 Q4 | 13.28 Million USD | -2.7% |
| 2016 Q3 | 13.65 Million USD | -25.22% |
| 2015 Q1 | 1.72 Million USD | -4.01% |
| 2015 FY | 18.19 Million USD | 909.67% |
| 2015 Q4 | 18.19 Million USD | 918.52% |
| 2015 Q3 | 1.78 Million USD | 1.61% |
| 2015 Q2 | 1.75 Million USD | 1.64% |
| 2014 Q4 | 1.8 Million USD | 0.93% |
| 2014 Q3 | 1.78 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 1.8 Million USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | 2.78 Million USD | 1010.32% |
| 2012 Q4 | 2.78 Million USD | 0.0% |
| 2011 FY | 250.65 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -3037.014% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -2627.012% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 19.442% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -352230.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -240.481% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -25806.618% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -29187.127% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -305.35% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 27.918% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -841.116% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | -24.047% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 76.674% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -15988.201% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -3765.387% |
| Molecular Templates, Inc. | 9.74 Million USD | -261.661% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -1782.391% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -84.785% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -740.081% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 66.232% |
| Statera Biopharma, Inc. | 11.43 Million USD | -208.219% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -4713.251% |
| Vaxxinity, Inc. | 13.26 Million USD | -165.669% |
| Vaccinex, Inc. | 26 Thousand USD | -135411.538% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |